Radionuclide imaging in drug development

Current Pharmaceutical Design

Volumn 10, Issue 24, 2004, Pages 2907-2921

  Perkins, Alan C ^a   Frier, Malcolm ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Drug biodistribution; Nuclear medicine; Radiolabelled drugs

Indexed keywords

ALBUMIN TC 99M; BOLTON HUNTER REAGENT I 125; BRAIN RECEPTOR; BUDESONIDE; CALCIUM PHOSPHATE; CARBON 11; CARBOPOL 940; CHLOROFLUOROCARBON; DRUG; DRUG CARRIER; EYE DROPS; FLUORINATED HYDROCARBON; FLUORINE 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDIUM 111; IODINE 123; LACTOSE; NITROGEN 13; OXYGEN 15; PENTETATE INDIUM IN 111; PENTETATE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; RADIOISOTOPE; SALBUTAMOL; SAMARIUM 153; SUCROSE; TECHNETIUM 99M; TECHNETIUM TIN COLLOID TC 99M; TRACER; UNINDEXED DRUG;

CORNEA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PENETRATION; DRUG UPTAKE; GASTROINTESTINAL TRACT; HUMAN; IMAGING; ISOTOPE LABELING; NEBULIZATION; NUCLEAR MEDICINE; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; REVIEW; SCINTILLATION CAMERA; TABLET DISINTEGRATION;

ANIMALS; DRUG DESIGN; HUMANS; PHARMACOLOGY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544231143     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383476     Document Type: Review

References (114)

1. Hardy JG. Radiolabeling of pharmaceutical dosage forms. In: Sampson CB, Ed. Textbook of Radiopharmacy: Theory and Practice, 3rd ed. Gordon and Breach Science Publishers 1990; 483-9.
2. Pim MV. Scintigraphic study of drug carriers and conjugates. In: Perkins AC, Frier MF, Eds. Nuclear Medicine in Pharmaceutical Research. London, Tyler and Francis Ltd 1999; 133-169
3. Kaempfer I. Chemistry of indium complexes. In: Deckart H, Cox PH, Eds. Principles of Radiopharmacology. Gustav Fischer: Verlag Jena 1987; 128-5.
4. Budisantoso N, Frier M, Wilson CG. Lipophilic drug models for scintigraphic evaluation of drug delivery systems. J Pharm Pharmacol 1997; 49 (suppl 4): 49.
5. Parr AF, Jay M. Radiolabeling of intact dosage forms by neutron activation: effects on in vitro performance. Pharm Res 1987; 4: 526-8.
6. Awang MB, Hardy JG, Davis SS, Wilding IR, Parry SJ. Radiolabeling of pharmaceutical dosage forms by neutron activation of samarium-512. J Labelledd Comp Radiompharm 1993; 33: 941-8.
7. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an evolving technology in pharmaceutical formulation development-Part 1. Pharm Sci Technol Today 1998; 1: 100-8.
8. Ito H, Pitcairn G, Hirst P, Newman S, Frier M, Perkins A. An in vivo study to assess the stability of technegas as a SPECT imaging agent for pulmonary drug formulations. Respiratory Drug Delivery 2002; 8: 133-6.
9. Okarvi SM. Recent progress in fluorine-18 labeled peptide radiopharmaceuticals. Eur J Nucl Med 2001; 28: 938.
10. Stöcklin G and Pike VW. Radiopharmaceuticals for positron emission tomography. Kluwer Academic Publishers Dordrecht 1993.
11. IPSM Report No. 44. An introduction to emission computed tomography, Institute of Physical Sciences in Medicine; York 1985.
12. AAPM Report No. 22. Rotating scintillation camera SPECT acceptance testing and quality control. American Association of Physicists in Medicine; New York 1987
13. Wallis JW, Miller TR. Three-dimensional display in nuclear medicine and radiology. J Nucl Med 1991; 32: 534-6.
14. Jarritt PH, Acton PD. PET imaging using gamma camera systems. Nucl Med Commun 1996; 17: 758-6.
15. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, et al. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 2002; 86: 1052-6.
16. Raven A, Clinical Trials, An Introduction. 2nd ed. Radcliffe Medical Press; New York 1993.
17. Publications of the International Commission on Radiological Protection (ICRP) 1990 Number 60 - Recommendations of the ICRP.
18. ICH Harmonized Tripartite Guideline for Good Clinical Practice. ICH Secretariat 1997.
19. Perkins AC, Pimm MV, MOD van der Kamp. Gamma Scintigraphy: A tool for reducing dissection and animal numbers in experimentation. In Animal alternatives, welfare and ethics, ed van Zutphen LFM and Balls M. Elsevier, Amsterdam 1997; 321-8.
20. Del Guerra A, Belcari N. Advances in animal PET scanners. Q J Nucl Med 2002; 46: 35-7.
21. Chatziioannou AF. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 2002; 29(1): 98-114.
22. Tolin RD, Malmud LS, Reilley J, Fisher RS. Esophageal scintigraphy to quantitate esophageal transit (quantitation of esophageal transit). Gastroenterology 1979; 76: 1402-8.
23. Blackwell JN, Hannan WJ, Adam RD, Heading RC. Radionuclide transit studies in the detection of esophageal dysmotility. Gut 1983; 24: 421-6.
24. Kazem I. A new scintigraphic technique for the study of the esophagus. Am J Roentgenol Radium Ther Nucl Med 1972; 115: 681-9.
25. Channer KS, Roberts CJC. The effect of posture at the time of administration on the efficacy of the hypnotic zopiclone. Br J Clin Pharmacol 1984; 18: 879-6.
26. Hey H, Jorgensen F, Sorensen K, Hasselbalch H, Wamberg T. Esophageal transit of six commonly used tablets and capsules. Br J Med 1982; 285: 1717-9.
27. Kikendall JW, Friedman AC, Oyewole MA, Fleischer D, Johnson LF. Pill-induced esophageal injury: Case reports and review of the medical literature. Dig Dis Sci 1983; 28(2): 174-82.
28. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Eng J Med 1996; 335: 1016-21.
29. Wamberg T, Jorgensen F, Hasselbalch H, Hey H. The rejudgment of the esophageal transfer of tablets and capsules. Arch Pharm Chem Sci Ed 1983; 11: 24-31.
30. Perkins AC, Wilson CG, Blackshaw PE, Vincent RM, Danscreau RJ, Juhlin KD, et al. Impaired esophageal transit of capsule versus tablet formulations in the elderly. Gut 1994; 35: 1363-7.
31. Marvola M, Vahervuo K, Sothmann A, Marttila E, Rajaniemi M. Development of a method for study of the tendency of drug products to adherence to the esophagus. J Pharm Sci 1982; 71: 975-7.
32. Swisher DA, Sendelbeck SL, Fara JW. Adherence of various oral dosage forms to the esophagus. Int J Pharmaceut. 1984; 22: 219-28.
33. Klein HA, Wald A. Normal variation in radionuclide esophageal transit studies, Eur J Nucl Med 1987; 13: 115-20.
34. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology 1984; 86: 1592-610.
35. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-92.
36. Wilding I, Hist P, Connor A. Development of a new engineering-based capsule for human drug absorption studies. Pharm Sci Technol Today 2000; 3: 385-92.
37. Parker G, Wilson CG, Hardy JG. The effect of capsule size and density on transit through the proximal colon, J Pharm Pharmacol 1988; 40: 376-7.
38. Hardy JG, Davis SS, Khosla R, Robertson CS. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int J Pharmacol 1988; 48: 79-82.
39. Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using radiopaque markers. Gut 1969; 10: 842-7.
40. Burkitt DP, Walker ARP, Painter NS. Effect of dietary fibre on stools and transit times, and its role in the causation of disease. Lancet 1972; (ii): 1408-12.
41. Cummings JH, Jenkins DJA, Wiggins HS. Measurement of the mean transit time of dietary residue through the human gut. Gut 1976; 17: 210-8.
42. Krevsky B, Malmud LS, D'Ercole F, Maurer AH, Fisher RS. Colonic transit scintigraphy: a Physiological approach to the quantitative measurement of colonic transit in humans. Gastroenterology 1986; 91: 1102-12.
43. Davis GR, Santa Ana CA, Morawski SG, Fordtran JS. Permeability characteristics of human jejunum, ileum, proximal colon and distal colon: results of potential difference measurements and unidirectional fluxes. Gastroenterology 1982; 83: 844-50.
44. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharmacol 1985; 25: 191-197.
45. Jay M, Digenis GA, Foster TS, Antonow DR. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease. Dig Dis Sci 1986; 31: 139-44.
46. Jarvinen T, Jarvinen K. Prodrugs for improved ocular drug delivery. Adv Drug Deliv Rev 1996; 19(2): 203-24.
47. Limberg M, Bugge C. Tear concentrations of topically applied ciprofloxacin. Cornea 1994; 13(6): 496-9.
48. Tang-Liu DDS, Schwob DL, Usansky JI, Gordon YJ. Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes. Clin Pharmacol Ther 1994; 55 (3): 284-92.
49. Bach FC, Adam JB, McWhirter HC, Johnson JE. Ocular retention of artificial tear solutions. Ann Ophthalmol 1972; 4: 116-9.
50. Chrai SS, Patton AM, Mehta A, Robinson JR. Lacrimal and instilled fluid dynamics in rabbit eyes. J Pharm Sci 1973; 62: 1112-21.
51. Rossomondo, RM, Carlton WH, Trueblood JH, Thomas, RP. A new method of evaluating lacrimal drainage. Arch Ophthalmol 1972; 88: 523-5.
52. Shell J. Therapeutic Review: Pharmacokinetics of topically applied of ophthalmic drugs. Surv Ophthalmol 1982; 26: 207-18.
53. Unlu N, Ludwig A, van Ooteghem M, Hincal AA. Formulation of carbopol-940 ophthalmic vehicles, and in vitro evaluation of the influence of simulated lacrimal fluid on their physicochemical properties. Pharmazie 1991; 46 (11): 784-788.
54. Wilson CG, Zhu YP, Frier M, Rao LS, Gilchrist P, Perkins AC. Ocular contact time of a carbomer gel, Geltears in man. Br J Ophthalmol 1998; 82 (10): 1131-4,
55. Wilson CG, Zhu YP, Frier M. Scintigraphic study of ocular drug delivery. In: Perkins AC, Frier M, eds. Nuclear Medicine in Pharmaceutical Research. London; Taylor and Francis Ltd 1999; 115-32.
56. Fitzgerald P, Wilson CG, Greaves JL, Frier M, Hollingsbee D, Gilbert D, Richardson M. Scintigraphic assessment of the precorneal residence of a new ophthalmic delivery system (NODS) in man. Int J Pharm 1992; 83: 177-85.
57. Snibson GR, Greaves JL, Soper NDW, Tiffany JM, Wilson CG, Bron AJ. Ocular surface residence times of artificial tear Solutions. Cornea 1992; 11(4): 288-93.
58. Meseguer G, Gurny R, Buri P, Rozier A, Plazonnet B. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. Int J Pharm 1993; 95: 229-34.
59. Meseguer G, Gurny R, Buri P. Gamma scintigraphic evaluation of precorneal clearance in human volunteers and in rabbits. Eur J Drug Metabol Pharmacokin 1993; 18: 190.
60. Meseguer G, Buri P, Plazonnet B, Rozier A, Gurny R. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 1996; 12 (4): 481-88,
61. Greaves JL, Wilson CG, Birmingham AT. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects. Br J Clin Pharm 1993; 35 (2): 188-92.
62. Stuart BO. Deposition of inhaled aerosols. Arch Int Med 1973; 131: 60-73.
63. Lay JC, Berry, CR, Kim, CS, Bennett WD. Retention of insoluble particles after local intrabronchial deposition in dogs. Journal of Applied Physiology 1995; 79: 921-9.
64. Agnew JE, Pavia D, Clarke SW. Factors affecting the 'alveolar deposition' of 5 μm inhaled particles in healthy subjects. Clinical Physics and Physiological Measurement 1985; 6: 27-36.
65. Burch WM, Sullivan PJ, McLaren, CJ. Technegas - a new ventilation agent for lung scanning. Nuc Med Commun 1986; 7: 865-71
66. Jones JG, Lawler P, Crawley JCW, Minty BD, Hulands G, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; 1: 66-8.
67. 99m lung radioactivity from planar images. Eur J Nuc Med 1993; 20: 10-5.
68. Fleming JS, Hashish AH, Conwa JH, Nassim MA, Holgate ST, Halson P, et al. Assessment of deposition of inhaled aerosol in the respiratory tract of man using three-dimensional multimodality imaging and mathematical modeling. J Aerosol Med 1996; 9: 317-27.
69. Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respiratory Medicine 1993; 87: 461-5.
70. Thomas SHL, Doherty MJ, Page CJ, Nunan TO, Bateman NT. Which apparatus r inhaled pentamidine? A comparison of pulmonary deposition via eight nebulizers. Eur Respir J 1991; 4: 616-22.
71. Everard ML, Hardy JG, Milner AD, Comparison of nebulized aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 1993; 48: 1045-6.
72. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994; 7: 2185-91.
73. Ashworth HL, Wilson CG, Sims EE, Wotton, PK, Hardy JG. Delivery of propellant soluble drug from a metered-dose inhaler. Thorax 1991; 46: 245-7.
74. Harnor KJ, Perkins AC, Wastie M, Wilson CG, Sims EE, Feely LC, et al. Effect of vapour pressure on the deposition patter from solution phase metered dose inhalers. Int J Pharmaceut 1993; 95: 111-6.
75. Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995; 40: 76-8.
76. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med 1993; 6: 99-110.
77. Pitcairn G, Lunghetti G, Ventura P, Newman S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int J Pharma 1994; 102: 11-8.
78. Proctor DF, Andersen I, Lundqvist G. Clearance of inhaled particles from the human nose. Arch Intern Med 1973; 131: 132-9.
79. Bond SW, Hardy JG, Wilson CG. Deposition and clearance of nasal sprays. Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics. Salamanca 1984: 93-8.
80. Sakakura Y, Ukai K, Majima Y, Murai S, Harada T, Miyoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngology 1983; 96: 167-73.
81. Lee SW, Hardy JG, Wilson CG, Smelt GJC. Nasal sprays and polyps. Nuc Med Commun 1984; 5: 697-703
82. Dondeti P, Zig H, Needham TE. Bioadhesive and formulation parameters affecting nasal absorption. Int J Pharmaceutics 1996; 127: 115-33.
83. Illum L, Jørgensen H, Bisgaard H, Krogsgaard O, Rossing, N. Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharmaceutics 1987; 39: 189-99.
84. Newman SP, Steed KP, Hardy JG, Wilding IR, Hooper G, Sparrow RA. The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques. J Pharm Pharmacol 1994; 46: 657-66.
85. Melchor R, Biddiscombe, MF, Mak VHF, Short MD, Spiro SG. Lung deposition patterns of directly labeled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506-11.
86. 123I-Labelled N-(2-Hydroxypropyl) Methacrylamide Copolymer-Doxorubicin Conjugate Containing Galactosamine Following Intravenous Administration to Nude Mice Bearing Hepatic Human Colon Carcinoma. J. Drug Targeting 1996; 3: 385-90.
87. Julyan PJ, Seymore LW, Ferry DR, Daryani S, Boivin CM, Doran J, et al. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Controlled Release 1999; 57: 281-90.
88. Ray P, Bauer E, Iyer M, Barrio JR, Satyamurthy N, Phelps ME, et al. Monitoring gene therapy with reporter gene imaging. Semin Nucl Med 2001; 31(4): 312-20. Review.
89. Wu JC, Inbushi M, Sundaresan G, Schelbert HR, Gambhir SS. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation 2002; 106: 180-83.
90. Iozzo P, Osman S, Glaser M, Knickmeier M, Ferrannini E, Pike VW, et al. In vivo imaging of insulin receptors by PET: preclinical evaluation of iodine-125 and iodine-124 labelled human insulin. Nucl Med Biol 2002; 29(1): 73-82.
91. Price JC, Kelley DE, Ryan CM, Meltzer CC, Drevets WC, Mathis CA, et al. Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study. Brain Res 2002; 927(1): 97-103.
92. Lee Ds. Lee SK. Lee MC. Functional neuroimaging in epilepsy: FDG PET and ictal SPECT. J Korean Med Sci 2001; 16: 689-96.
93. Raffel DM. Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol 2001; 28: 541-59.
94. Reske SN, Kotzerke J. FDG-PET for clinical use. Result of the 3rd German Interdisciplinary Consensus Conference. Eur J Nucl Med 2001; 28: 1707-23.
95. Willis MW, Ketter TA, Kimbrell TA, George MS, Herscovitch P, Danielson AL, et al. Age, Sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res 2002; 114 (1): 23-37.
96. Laverman P, Boerman OC, Corstens FM, Oyen WJG. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med 2002; 29: 681-90.
97. Mankoff DA, Dunnwald LK, Gralow JR, Charlop A, Lawton TJ, Schubert EK, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43: 500-9.
98. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000; 1: 156-63.
99. Dose J. Hemminger GE. Bohuslavizki KH. Therapy monitoring using FDG-PET in metastasic cervical cancer. Lancet Oncol 2002; 1: 106.
100. Keiding S, Munk OL, Roelsgaard K, Bender D, Bass L. Positron emission tomography of hepatic first-pass metabolism of ammonia in pig. Eur J Nucl Med 2001; 28 (12): 1770-75.
101. Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in neurosychopharmacological drug development. Curr Pharm Des 2001; 7: 1907-29.
102. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002; 59 (6): 514-20.
103. Doudet DJ, Jivan S, Ruth TJ, Holden JE. Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 2002; 44: 198.
104. Doze P, Elsinga PH, Maas B, Van Waarde A, Wegman T, Vaalburg W. Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET. Neurochem Int 2002; 40: 145-55.
105. Brown LL, Kulkarni S, Pavlova QA, Koren AO, Mukhin AG, Newman AH, et al. Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(s)-pyrrolidinyl)methoxy)-3- (2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. J Med Chem 2002; 45: 2841-49.
106. Schonbachler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, et al. PET imaging of dopamine transporters in the human brain using [(11)C]-beta-CPPIT, a cocaine derivative lacking the 2 beta-ester function. Nucl Med Biol 2002; 29(1): 19-27.
107. Rabiner EA, Wilkins MR, Turkheimer F, Gunn RN, De Haes JU, De Vries M, et al. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4[4-(7-chloro-2,3-dihidro-1,4-benzdioxyn-5-yl)-1-piperazinyl] butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][0-methyl-3H]-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther 2002; 301: 1144-50.
108. Brady F, Luthra SK, Brown GD, Osman S, Aboagye E, Saleem A, et al. Radiolabeled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des 2001; 7 (18): 1863-92.
109. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, et al. Imaging. TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia 2001; 3(6): 480-8.
110. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F] fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168 (1): 273-80.
111. Johnson SD, Welch MJ. Investigations into tumour accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. Nucl Med Biol 2002; 29: 211-16.
112. Bailey DL, Adamson KL. Nuclear medicine: from photons to physiology. Curr Pharm Design 2003; 9(11): 903-16.
113. Podoloff DA. Diagnostic and therapeutic applications of radiolabeled somatostatin analogs: current status in an oncology center. Curr Pharm Design 2002; 8(20): 1809-14.
114. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Design 2002; 8(20): 1781-807.